An Overview
Dr. Lori Styles, MD, is the director of the pediatric sickle cell program, and her research interests are in translational and clinical sickle cell disease research. Dr. Styles’ current research focuses on therapies for acute chest syndrome (ACS), a major cause of mortality in sickle cell patients that occurs without warning, and upregulation of nitric oxide in sickle cell disease.
The overall PI for the Comprehensive Sickle Cell Center’s multi-institution study to evaluate oral arginine as prophylactic therapy, Dr. Styles is investigating the effects of arginine in sickle cell patients with ACS. In collaboration with Frans Kuypers, PhD, Dr. Styles discovered a potential target for drug therapy in ACS and is now investigating the use of infliximab (a TNF inhibitor) to prevent onset of ACS.
© 2005 Children's Hospital Oakland Research Institute
5700 Martin Luther King Jr Way • Oakland, California 94609
Phone 510-450-7600 • Fax 510-450-7910
Site Map
• Disclaimer
• CHORI
Intranet • Email Webmaster